This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

BioMarin Announces Fourth Quarter And Full Year 2013 Financial Results

Total Revenue Grows 9.5% in 2013 U.S. Commercial Launch of VIMIZIMâ„¢ Underway; Positive CHMP Opinion Received February 20

Financial Highlights ($ in millions, except per share data, unaudited)
  Three Months Ended December 31, Twelve Months Ended December 31,
  2013 2012 % Change 2013 2012 % Change
             
Total BioMarin Revenue  $ 146.9  $ 131.9 11.4%  $ 548.5  $ 500.7 9.5%
Total BioMarin Revenue             
(excluding Aldurazyme Net Product Transfer Revenue) - non-GAAP  148.5  131.2 13.2%  553.4  498.9 10.9%
Naglazyme Net Product Revenue  68.7  63.0 9.0%  271.2  257.0 5.5%
Aldurazyme BioMarin Net Product Revenue   25.9  24.6 5.3%  83.6  82.2 1.7%
Aldurazyme Royalty Revenue            
(excluding Net Product Transfer Revenue) - non-GAAP  27.5  23.9 15.1%  88.5  80.4 10.1%
Kuvan Net Product Revenue  45.3  40.0 13.3%  167.4  143.1 17.0%
Firdapse Net Product Revenue  4.3  3.4 26.5%  16.1  14.2 13.4%
VIMIZIM  0.1  --     0.1  --   
             
Non-GAAP Net Loss  $ (15.8)  $ (15.5)    $ (40.4)  $ (11.6)  
Non-GAAP Net Loss per Share (basic)  $ (0.11)  $ (0.12)    $ (0.29)  $ (0.10)  
Non-GAAP Net Loss per Share (diluted)  $ (0.11)  $ (0.12)    $ (0.30)  $ (0.12)  
             
GAAP Net Loss   $ (62.0)  $ (53.0)    $ (176.4)  $ (114.3)  
GAAP Net Loss per Share (basic)  $ (0.43)  $ (0.43)    $ (1.28)  $ (0.95)  
GAAP Net Loss per Share (diluted)  $ (0.44)  $ (0.43)    $ (1.28)  $ (0.95)  
             
Cash, cash equivalents and investments *        $1,052.4  $ 563.8 86.7%
* The cash balance at the end of 2013 includes net proceeds of $696.4 million from the Convertible Debt offering in October 2013.

SAN RAFAEL, Calif., Feb. 26, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced financial results for the fourth quarter and full year 2013.  Non-GAAP net loss was $15.8 million ($0.11 per share, basic and diluted) for the fourth quarter of 2013, compared to non-GAAP net loss of $15.5 million ($0.12 per share, basic and diluted) for the fourth quarter of 2012. GAAP net loss was $62.0 million ($0.43 per share, basic and $0.44 per share, diluted) for the fourth quarter of 2013, compared to GAAP net loss of $53.0 million ($0.43 per share, basic and diluted) for the fourth quarter of 2012. The increased non-GAAP net loss and GAAP net loss for the fourth quarter of 2013 compared to the fourth quarter of 2012 was primarily due to increased research and development expenses, including costs associated with PEG PAL, BMN 673 and BMN 270, the Company's AAV-factor VIII gene therapy drug candidate for the treatment of hemophilia A, as well as increased selling, general and administrative expenses, including costs associated with VIMIZIM launch activities, partially offset by increased net product revenues.

1 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,596.35 -350.33 -1.95%
S&P 500 2,057.64 -43.85 -2.09%
NASDAQ 4,958.4680 -122.0370 -2.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs